- Quantum BioPharma (CSE:QNTM) has entered into an agreement with Ingenu CRO Pty to conduct a clinical study for the purpose of observing disease progression in patients with primary progressive multiple sclerosis
- This study aims to enable a future phase 2 clinical trial with Lucid-21-302 (Lucid-MS)
- Quantum BIoPharma is focused on innovative treatments for neuro disorders
- Shares of Quantum BIoPharma are down 5.71 per cent to C$5.28 as of 11:54 am ET
Quantum BioPharma (CSE:QNTM) has entered into an agreement with Ingenu CRO Pty to conduct a clinical study for the purpose of observing disease progression in patients with primary progressive multiple sclerosis.
In a news release, the company stated this study aims to enable a future phase 2 clinical trial with Lucid-21-302 (Lucid-MS).
Lucid 21-302 is Quantum’s lead compound that has been demonstrated in preclinical models to prevent and reverse myelin degradation, which is a cause of multiple sclerosis. It has also been tested in other neurodegenerative diseases and conditions.
“We are very pleased to be working with Ingenu CRO to conduct this observational study in patients with multiple sclerosis,” Andrzej Chruscinski, vice president of scientific and clinical affairs at Quantum BioPharma, said in a statement. “This is an important study that advances our multiple sclerosis research program and moves us closer to initiating a phase 2 clinical trial with Lucid-21-302.”
Lucid 21-302 is a new chemical entity for multiple sclerosis pre-clinical research that has re-established the use of paralyzed rear legs in multiple sclerosis mouse models, while research has been previously published in peer-reviewed journals.
In January 2023 the company submitted its phase-1 Clinical Trial Application of the compound for first-in-human safety and tolerability investigation.
Formerly FSD Pharma, Quantum BioPharma operates in two segments: biotechnology and strategic investments.
Its biotechnology segment is focused on furthering the research and development of its two primary drug candidates, including Lucid 21-302 and Lucid-PSYCH, as well as the development of UNBUZZD.
Shares of Quantum BIoPharma (CSE:QNTM) are down 5.71 per cent to C$5.28 as of 11:54 am ET.
Join the discussion: Find out what everybody’s saying about this stock on the Quantum BIoPharma Ltd. Bullboard investor discussion forum, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
(Top image: Adobe Stock)